
Natasha A Jain

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6529574/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<p>Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers</p> . Cancer Management and Research, 2020, Volume 12, 11743-11749.	0.9	5
2	Framingham Risk Score Is an Ineffective Screening Strategy for Coronary Heart Disease in Long-Term Allogeneic Hematopoietic Cell Transplant Survivors. Clinical Hematology International, 2020, 2, 109.	0.7	2
3	Premature coronary artery disease following allogeneic stem cell transplantation: an NHLBI Cohort Study. Bone Marrow Transplantation, 2019, 54, 320-322.	1.3	0
4	Immunotherapy in inoperable stage III non-small cell lung cancer: a review. Drugs in Context, 2019, 8, 1-6.	1.0	9
5	Recurrent and de-novo autoimmune hemolytic anemia in patients treated with immunotherapy for advanced cancer Journal of Clinical Oncology, 2019, 37, e14170-e14170.	0.8	0
6	Clinical Risk Factor Modeling for Late Coronary Artery Disease—An NHLBI Allogeneic Stem Cell Transplant Survivorship Cohort Study. Biology of Blood and Marrow Transplantation, 2017, 23, S223-S224.	2.0	0
7	Treatment of refractory delayed onset heparinâ€induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG). Research and Practice in Thrombosis and Haemostasis, 2017, 1, 134-137.	1.0	16
8	Factors influencing the late phase of recovery after bone mineral density loss in allogeneic stem cell transplantation survivors. Bone Marrow Transplantation, 2016, 51, 1101-1106.	1.3	20
9	CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation. Supportive Care in Cancer, 2016, 24, 815-822.	1.0	6
10	Association of Comprehensive Lipoprotein Profiling with Coronary Artery Disease in Allogeneic Stem Cell Transplant (Allo-SCT) Survivors. Blood, 2016, 128, 828-828.	0.6	1
11	Reduced Non Relapse Mortality (NRM) and Survivable Acute Graft Versus Host Disease (GVHD) in the Current Era of Myeloablative Ex Vivo T-Cell Depleted (TCD) Transplantation. Blood, 2016, 128, 4596-4596.	0.6	0
12	Blood Stream Infection Is Frequent during Conditioning but Does Not Impact Allogeneic Transplant Outcomes in the Modern Era. Biology of Blood and Marrow Transplantation, 2015, 21, S268.	2.0	0
13	Minor ABO Incompatibility Does Not Impact Non-Relapse Mortality in T-Cell Depleted HLA-Matched Sibling Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, S276-S277.	2.0	0
14	Clinical and laboratory predictors impacting allogeneic peripheral blood stem cell mobilization. Cytotherapy, 2015, 17, S66.	0.3	0
15	A Rare Consequence of Chronic Graft Versus Host Disease - Peyronie's Disease. Archives in Cancer Research, 2015, 3, .	0.3	9
16	Cardiac CT Imaging Is a Feasible Screening Strategy for Coronary Artery Disease (CAD) in Long Term Allogeneic Stem Cell Transplant (Allo-SCT) Survivors. Biology of Blood and Marrow Transplantation, 2015, 21, S73.	2.0	0
17	Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. Bone Marrow Transplantation, 2015, 50, 189-196.	1.3	7
18	A multigene array for measurable residual disease detection in AML patients undergoing SCT. Bone Marrow Transplantation, 2015, 50, 642-651.	1.3	33

NATASHA A JAIN

#	Article	IF	CITATIONS
19	Minor ABO Incompatibility Does Not Impact Nonrelapse Mortality in T Cell–Depleted Human Leukocyte Antigen–Matched Sibling Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 954-955.	2.0	1
20	Clinical comorbidity predictive measures in ex vivo T-cell-depleted allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2015, 50, 1138-1140.	1.3	3
21	Bone Mineral Density (BMD) Improves in Survivors in Their Second Decade Post-Allogeneic Stem Cell Transplantation and Is Influenced By Body Mass Index (BMI) and Age. Biology of Blood and Marrow Transplantation, 2015, 21, S171.	2.0	0
22	Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete Allohsct. Blood, 2015, 126, 3212-3212.	0.6	0
23	Contrast enhanced cardiac CT reveals coronary artery disease in 45% of asymptomatic allo-SCT long-term survivors. Bone Marrow Transplantation, 2014, 49, 451-452.	1.3	9
24	Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. Leukemia, 2014, 28, 1167-1170.	3.3	33
25	Radiation exposure from diagnostic procedures following allogeneic stem cell transplantation – How much is acceptable?. Hematology, 2014, 19, 275-279.	0.7	5
26	Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. Experimental Hematology, 2014, 42, 83-89.	0.2	26
27	The clinical and financial burden of pre-emptive management ofÂcytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approaches. Cytotherapy, 2014, 16, 927-933.	0.3	56
28	Repair of Impaired Pulmonary Function Is Possible in Very-Long-Term Allogeneic Stem Cell Transplantation Survivors. Biology of Blood and Marrow Transplantation, 2014, 20, 209-213.	2.0	13
29	The Clinical and Financial Cost of Preemptive Management of CMV Disease – Implications for Immunotherapy. Biology of Blood and Marrow Transplantation, 2014, 20, S128.	2.0	0
30	A Novel Multi-Gene Array Allows Relapse Risk Stratification in Acute Myeloid Leukemia Patients Undergoing Stem Cell Transplantation. Blood, 2014, 124, 667-667.	0.6	0
31	Clinical Comorbidity Measures and Predictive Scores in Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 2550-2550.	0.6	0
32	Post-Transplant Pulmonary Function Abnormalities Nadir At Five Years and Then Fully Normalize by the Second Decade in Allogeneic Stem Cell Transplantation Survivors. Biology of Blood and Marrow Transplantation, 2013, 19, S151.	2.0	0
33	Comorbidity Measures In Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (HCT). Blood, 2013, 122, 2124-2124.	0.6	3
34	Contrast Enhanced Cardiac CT Detects Coronary Artery Disease In 44% Of Asymptomatic Long-Term Adult Allogeneic Stem Cell Transplant Survivors. Blood, 2013, 122, 2080-2080.	0.6	0
35	Post-Transplant Pulmonary Function Abnormalities Normalize in Survivors by the Second Decade After Allogeneic Stem Cell Transplantation. Blood, 2012, 120, 1967-1967.	0.6	0